Jounce Therapeutics, Inc. (JNCE) financial statements (2021 and earlier)

Company profile

Business Address 780 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments169190236
Cash and cash equivalents534824
Short-term investments116142212
Receivables 018
Prepaid expense 22
Other current assets  0
Other undisclosed current assets5  
Total current assets:174192256
Noncurrent Assets
Operating lease, right-of-use asset18
Property, plant and equipment111416
Long-term investments and receivables2622
Long-term investments2622
Other noncurrent assets233
Total noncurrent assets:322241
TOTAL ASSETS:206214297
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities111011
Accounts payable233
Accrued liabilities978
Debt3  
Deferred rent credit 0
Deferred revenue and credits51
Contract with customer, liability55
Other liabilities000
Total current liabilities:146663
Noncurrent Liabilities
Long-term debt and lease obligation17  
Operating lease, liability17
Liabilities, other than long-term debt 4567
Deferred revenue and credits67
Contract with customer, liability43
Deferred rent credit 2
Other liabilities  0
Total noncurrent liabilities:174567
Total liabilities:31110130
Stockholders' equity
Stockholders' equity attributable to parent175104167
Common stock000
Additional paid in capital282268257
Accumulated other comprehensive income (loss)0(0)(0)
Accumulated deficit(107)(164)(90)
Total stockholders' equity:175104167
TOTAL LIABILITIES AND EQUITY:206214297

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Revenue, net72
Revenue from related parties14865
Gross profit:1486572
Operating expenses(95)(96)(91)
Operating income (loss):53(31)(19)
Nonoperating income
(Other Nonoperating income)
443
Income (loss) from continuing operations before income taxes:57(27)(16)
Income tax expense(0)(0)(0)
Net income (loss) attributable to parent:57(27)(16)
Other undisclosed net loss available to common stockholders, basic  (1)
Net income (loss) available to common stockholders, diluted:57(27)(17)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net income (loss):57(27)(16)
Comprehensive income (loss):57(27)(16)
Other undisclosed comprehensive income, net of tax, attributable to parent000
Comprehensive income (loss), net of tax, attributable to parent:57(27)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: